October 16th 2023
The 5th Annual Advanced Practice Collaborative™
Collaborating Across the Continuum™ : Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
Clinical Consultations™: Raising Awareness and Optimizing Treatment in Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Addressing Healthcare Inequities: Overcoming Challenges in the Equitable Management of Idiopathic Pulmonary Fibrosis
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
Biopharmaceutical company, Barinthus Biotherapeutics, studied its investigational immunization candidate, VTP-300, together with Arbutus Biopharma’s hepatitis B (HBV) therapeutic, imdusiran.
A study demonstrates the microbiome changes and how restoration of the gut flora is warranted when patients are dealing with recurrent bouts of the health care-associated infection.
This week we covered antibiotic de-escalation, the approved fecal microbiota options for prevention of recurrent Clostridioides difficile, the CDC's recommendations for HCV testing in the pediatric populations, and examining pragmatic approaches to skin and soft tissue Infections.
At the American Association for the Study of Liver Diseases (AASLD) meeting held last week, Barinthus Biotherapeutics announced the presentation of data from its hepatitis B clinical trials.
The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
The investigational agent, afabicin, was developed by private company, Debiopharm, and a clinician offers some insights on the therapy in these 2 therapeutic areas.
Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.
This week read about virus testing, the dosing of one of the COVID-19 vaccines in the pediatric population, HAI grades in hospitals, and live biotherapeutic products in preventing recurrent CDI in older adults with comorbidities.